Relmada Therapeutics, Inc. (RLMD) Dividend History

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of central nervous system (CNS) disorders. The company leverages its expertise in pain management and neuropharmacology to develop innovative drug candidates aimed at addressing unmet medical needs in chronic pain and related conditions.

2222 Ponce De Leon Blvd. 3rd Floor, Coral Gables, FL, 33134
Phone: 646 876 3459
Website: https://www.relmada.com

Dividend History

Relmada Therapeutics, Inc. currently does not pay dividends

Company News

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Relmada Therapeutics announced positive Phase 2 data for its investigational drug NDV-01 in patients with high-grade non-muscle invasive bladder cancer. The data showed strong clinical activity and favorable tolerability, supporting further development of NDV-01.

GlobeNewswire Inc.
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Relmada Therapeutics announced the discontinuation of its Reliance II and Relight Phase 3 studies for REL-1017 due to recent data monitoring committee evaluation. The company will continue to advance the Phase 1 study of REL-P11 and explore strategic alternatives to maximize shareholder value.

Benzinga
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.

Zacks Investment Research

Featured Companies: ANIK ANVS CORT
Here's Why Relmada Therapeutics Stock Popped Today

Results from a human abuse potential study with REL-1017 exceeded expectations.

The Motley Fool

Page data last updated 07/24/2025 01:31:35 UTC